We compare two types of pancreatic carcinoma samples obtained by EUS-guided fine needle biopsy (EUS-FNB) in terms of the success rates and clinical validity of analysis of two most commonly investigated DNA/RNA pancreatic cancer markers, KRAS mutations and miR-21 expression. 118 patients with pancreatic ductal adenocarcinoma underwent EUS-FNB. The collected sample was divided, one part was stored in a stabilizing solution as native aspirate (EUS-FNA) and second part was processed into the cytological smear (EUS-FNC). DNA/RNA extraction was followed by analysis of KRAS mutations and miR-21 expression. For both sample types, the yields of DNA/RNA extraction and success rates of KRAS mutation and miRNA expression were evaluated. Finally, the resulting KRAS mutation frequency and miR-21 prognostic role were compared to literature data from tissue resections. The overall amount of isolated DNA/RNA from EUS-FNC was lower compared to the EUS-FNA, average yield 10 ng vs 147 ng for DNA and average yield 164 vs. 642 ng for RNA, but the success rates for KRAS and miR-21 analysis was 100% for both sample types. The KRAS-mutant detection frequency in EUS-FNC was 12% higher than in EUS-FNA (90 vs 78%). The prognostic role of miR-21 was confirmed in EUS-FNC (p = 0.02), but did not reach statistical significance in EUS-FNA (p = 0.06). Although both types of EUS-FNB samples are suitable for DNA/RNA extraction and subsequent DNA mutation and miRNA expression analysis, reliable results with clinical validity were only obtained for EUS-FNC.

Centre for Applied Genomics of Solid Tumors Genomac Research Institute 161 00 Prague CZ Czech Republic

Department of Internal Medicine 1st Faculty of Medicine of Charles University and Military University Hospital 169 02 Prague CZ Czech Republic

Pathology department Military University Hospital 169 02 Prague CZ Czech Republic

Zobrazit více v PubMed

Am J Gastroenterol. 2011 Dec;106(12):2104-11 PubMed

PLoS One. 2010 May 14;5(5):e10630 PubMed

Pancreas. 2013 Jan;42(1):67-71 PubMed

Clin Chem. 2010 Apr;56(4):603-12 PubMed

J Clin Pathol. 2013 Mar;66(3):192-7 PubMed

Clin Cancer Res. 2012 Feb 15;18(4):981-92 PubMed

Anticancer Res. 2009 May;29(5):1803-10 PubMed

J Gastrointest Oncol. 2012 Jun;3(2):105-19 PubMed

Diagn Pathol. 2015 Apr 24;10:38 PubMed

Gastroenterol Res Pract. 2015;2015:892903 PubMed

Hum Gene Ther. 2009 Aug;20(8):831-44 PubMed

Clin Chem. 2008 Oct;54(10):1716-24 PubMed

J Clin Endocrinol Metab. 2015 Jul;100(7):2743-50 PubMed

Eur J Cancer. 2015 Jul;51(11):1389-404 PubMed

Am J Gastroenterol. 2002 Sep;97(9):2263-70 PubMed

Clin Gastroenterol Hepatol. 2014 Oct;12(10):1717-23 PubMed

Gastrointest Endosc. 2005 Jan;61(1):76-9 PubMed

Br J Cancer. 2014 Aug 26;111(5):817-22 PubMed

Arq Bras Endocrinol Metabol. 2013 Aug;57(6):490-1 PubMed

Methods. 2001 Dec;25(4):402-8 PubMed

Nature. 2012 Nov 15;491(7424):399-405 PubMed

Gut. 2011 Jun;60(6):861-8 PubMed

J Gastrointest Surg. 2008 Dec;12(12):2171-6 PubMed

Aliment Pharmacol Ther. 2003 May 15;17(10):1299-307 PubMed

Clin Cancer Res. 2012 Jan 15;18(2):534-45 PubMed

World J Gastroenterol. 2007 Jul 21;13(27):3714-20 PubMed

Pancreatology. 2011;11(5):482-6 PubMed

Nat Med. 2013 Aug;19(8):949-50 PubMed

World J Gastrointest Endosc. 2015 Apr 16;7(4):318-27 PubMed

Prognostic Role of Specific KRAS Mutations Detected in Aspiration and Liquid Biopsies from Patients with Pancreatic Cancer

Diabetes Mellitus in Pancreatic Cancer: A Distinct Approach to Older Subjects with New-Onset Diabetes Mellitus

Detection and Quantification of ctDNA for Longitudinal Monitoring of Treatment in Non-Small Cell Lung Cancer Patients Using a Universal Mutant Detection Assay by Denaturing Capillary Electrophoresis